Clinical Impact of Digitalis Therapy in a Large Multicenter Cohort of CRT-Recipients

Julia W Erath1, Nikolett Vigh2, Balazs Muk2,3

  • 1Department of Cardiology, Goethe University Hospital, 60590 Frankfurt am Main, Germany.

Insights

Digitalis therapy in patients with cardiac resynchronization therapy (CRT) did not affect mortality. However, it was linked to a poorer CRT response and increased ventricular arrhythmias, though it reduced cardiac rehospitalization.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Devices

Background:

  • The use of digitalis in severe heart failure patients receiving cardiac resynchronization therapy (CRT) remains controversial.
  • Observational studies are crucial for understanding digitalis effects in this complex patient population.

Purpose of the Study:

  • To assess the impact of digitalis therapy on all-cause mortality in patients undergoing CRT.
  • To evaluate secondary endpoints including CRT response, echocardiographic improvements, ICD shocks, and rehospitalization rates.

Main Methods:

  • A large, observational study involving 552 consecutive CRT-defibrillator recipients across three European centers.
  • Digitalis use was recorded at CRT implantation; follow-up averaged 37 months.
  • Multivariate Cox-regression and propensity score matching were employed to analyze mortality and secondary outcomes.

Main Results:

  • Digitalis users (40%) had more comorbidities like atrial fibrillation, lower ejection fraction (LVEF), and higher NYHA class.
  • No significant difference in all-cause mortality was observed between digitalis users and non-users, even after adjustment (adjusted HR=1.04) and propensity matching (HR=1.11).
  • Digitalis was associated with reduced CRT response (NYHA class and LVEF improvement) and increased ventricular arrhythmias requiring ICD shocks, but significantly lower cardiac rehospitalization (HR=0.58).

Conclusions:

  • Digitalis therapy demonstrated no impact on mortality in CRT recipients.
  • The therapy was linked to diminished CRT response and increased susceptibility to ventricular arrhythmias requiring ICD shocks.
  • Digitalis use was associated with a positive effect on reducing cardiac rehospitalization during follow-up.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Pulse rhythm01:30

Pulse rhythm

Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
782